ProMIS Neurosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMN research report →
Range $29 – $33
Price Chart
About the company
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins.
- CEO
- Neil K. Warma
- IPO
- 2007
- Employees
- 11
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on PMN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $28.43M
- P/E
- -0.34
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.70
- EV/EBITDA
- 0.38
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -103.07%
- ROIC
- -96.37%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-40,167,308
- Net Income
- $-39,719,147-1529.3%
- EPS
- $-22.61-922.2%
- OCF Growth
- -3.4%
- FCF Growth
- -3.4%
- 52W High
- $27.40
- 52W Low
- $2.78
- 50D MA
- $8.17
- 200D MA
- $12.31
- Beta
- -0.21
- RSI (14)
- 30
- Avg Volume
- 164.88K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Promise Neuroscience said PRECISE AD is nearing completion, with Q1 2027 top-line data expected, and framed PMN310 as a potentially safer anti-amyloid therapy if it can preserve efficacy while reducing ARIA.· November 12, 2026
- All patient visits in PRECISE AD are expected to conclude this quarter, and unblinded 12-month top-line data remain on track for Q1 2027.
- The company highlighted 6-month interim data from 136 safety-evaluable patients: no ARIA-E in any APOE genotype, ARIA-H at 4.4%, no drug-related discontinuations, and no treatment-related serious adverse events.
- Biomarker signals from the interim read included plasma p-tau217 down about 15% from baseline and CSF MTBR tau 243 down about 13%, which management said supports target engagement.
- Cash was approximately $44.1 million at quarter end, which management said should fund operations through 2027 and beyond the PRECISE AD readout.
- Management is already planning next steps, including an FDA meeting after full analysis, subcutaneous formulation work, and a potential registrational study as early as late 2027 subject to FDA feedback.
Promise reported Q3 net loss of $8.2 million, or $0.89 per share, versus $11.6 million, or $5.93 per share, a year ago. For the first 9 months, net loss was about $28.1 million, or $3.39 per share, versus $29 million, or $19.58 per share in 2025. R&D expense was approximately $6.7 million, down 32% from $9.8 million a year ago, mainly due to a $3.6 million reduction in direct PMN310 costs as the PRECISE AD trial moved toward completion. G&A was approximately $1.9 million, roughly flat with $2.0 million last year, and other income rose to about $500,000 from $200,000 on higher interest income. Cash was approximately $44.1 million at quarter end, and management said this should fund operations through 2027. The company did not give revenue because it is a clinical-stage biotech with no product sales. Forward guidance centered on completion of patient visits this quarter, Q1 2027 unblinded top-line data, an FDA meeting after full data analysis, ongoing subcutaneous formulation development, and preparation for a potential registrational study toward the end of 2027, subject to FDA feedback.
Neil Warma said Promise is entering what he described as the most important period in its history, with PRECISE AD nearing completion and the key readout expected in Q1 2027. His message was that PMN310 is designed to be meaningfully different from plaque-clearing antibodies because it is intended to selectively target toxic amyloid beta oligomers while avoiding plaque and the associated ARIA burden. He emphasized that the company is not waiting for the data to start planning the next phase, citing FDA fast track status, subcutaneous formulation work, and a strengthened leadership team.
The financial discussion emphasized runway and spending discipline. Management said cash was approximately $44.1 million at quarter end and expects that to fund operations through 2027, beyond the PRECISE AD readout. R&D fell to about $6.7 million from $9.8 million a year ago due mainly to a $3.6 million reduction in direct PMN310 costs as the trial neared completion, while G&A was about $1.9 million, roughly flat year over year, and other income increased to about $500,000 on higher interest income. Net loss was $8.2 million, or $0.89 per share, versus $11.6 million, or $5.93 per share, last year.
Analysts focused on what would count as a meaningful efficacy signal, how the 140-patient, 12-month study compares with larger trials, and how management would judge go/no-go decisions. Warma said the company will weigh the totality of safety, clinical outcomes, biomarkers, and mechanism data, with a particular focus on ARIA rates near placebo and directional efficacy in iADRS or CDR-SB, and he suggested roughly 15% to 20% efficacy would be viewed as meaningful if paired with a better safety profile. Other questions centered on whether binding oligomers implies neutralization, how the Fc backbone matters, and how the company’s new oligomer assay differs from antibody-saturation readouts; Altstiel said PMN310’s binding and microglial clearance likely work together and that the new assay measures absolute CSF oligomer concentrations rather than inferential saturation. Management also addressed MRI monitoring, saying they hope reduced ARIA could support fewer scans but that the eventual label will depend on FDA review and future data.
The bull case from this call is that management believes PMN310 may finally test the “oligomer-selective” hypothesis in humans, and that its interim safety profile already looks cleaner than approved anti-amyloid drugs. The company also has enough cash to reach the key Q1 2027 readout, while already lining up regulatory and manufacturing next steps if the data are favorable.
The main risk is that the final readout may not confirm the early safety and biomarker signals, and management repeatedly cautioned that interim data are not definitive. There is also no top-line efficacy data yet, and the company acknowledged that a 140-patient phase 1b study is not directly comparable to larger late-stage trials, so the go/no-go decision may still depend on a nuanced package of safety, efficacy, biomarkers, and FDA feedback.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 78.4%
- Shares Outstanding
- 9.00M
- Float Shares
- 7.05M
of shares held by institutions
27 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jupiter Topco LLC | 1.29M | ▲ 1.29M |
| Janus Henderson Group Ltd. | 1.29M | ▲ 1.29M |
| Deep Track Capital, LP | 740.12K | ▼ 95.54K |
| Wellington Management Group Llp | 696.38K | 0 |
| Ally Bridge Group (Ny) LLC | 620.32K | 0 |
| Adage Capital Partners Gp, L.L.C. | 564.27K | ▲ 400.00K |
| Trails Edge Capital Partners, LP | 557.10K | 0 |
| Yu Fan | 329.76K | 0 |
| Woodline Partners LP | 314.60K | ▼ 127.31K |
| Sphera Funds Management Ltd. | 254.78K | ▼ 70.81K |
| 683 Capital Management, LLC | 250.00K | ▲ 155.00K |
| Ikarian Capital, LLC | 205.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 4, 26 | Williams Eugene | buy | 26,500 |
| Oct 30, 26 | Williams Eugene | buy | 1,316 |
| Nov 2, 26 | Cashman Neil | buy | 10,000 |
| Oct 5, 26 | Rubino Ivana | other | 80,000 |
| Oct 5, 26 | Rubino Ivana | other | 0 |
| Aug 5, 26 | Kaplan Johanne | buy | 2,280 |
| May 20, 26 | WYMAN WILLIAM W | other | 11,000 |
| May 20, 26 | WYMAN WILLIAM W | other | 5,500 |
| May 20, 26 | Williams Eugene | other | 11,000 |
| May 20, 26 | Williams Eugene | other | 5,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PMN coverage
Recent articles, reports, and earnings notes.
No research on PMN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PMN report →ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
globenewswire.com · Nov 17
ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
globenewswire.com · Nov 12
ProMIS Neurosciences to Participate in Upcoming Conferences in November
globenewswire.com · Nov 5
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
zacks.com · Nov 4
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
globenewswire.com · Nov 3
Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to Trade
zacks.com · Oct 29
ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
globenewswire.com · Oct 6
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
globenewswire.com · Sep 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.